Payment overview · 2025
General Payments
$265.99
8 reported records · 2 companies
Healthcare provider profile · identity verified
Karlene Hertle Bert, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MODESTO, CA · NPI 1053511378
Verified facts
What the public records show
CMS Open Payments records show Karlene Hertle Bert, NURSE PRACTITIONER received $265.99 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 62.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tezspire.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Tezspire by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $165.92 | 62.4% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $100.07 | 37.6% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.99 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $165.92 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $100.07 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
187 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 697 | 72 |
| Alendronate Sodium | Alendronate Sodium | 680 | 73 |
| Losartan Potassium | Losartan Potassium | 417 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 42 |
| Fenofibrate | Fenofibrate | 334 | 30 |
| Metformin Hcl | Metformin Hcl | 301 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 51 |
| Atenolol | Atenolol | 221 | 25 |
| Vascepa | Icosapent Ethyl | 219 | 28 |
| Gabapentin | Gabapentin | 214 | 26 |
| Simvastatin | Simvastatin | 201 | 17 |
| Tezspire | Tezepelumab-Ekko | 187 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 179 | 82 |
| Omeprazole | Omeprazole | 159 | 21 |
| Arnuity Ellipta | Fluticasone Furoate | 153 | 22 |
| Furosemide | Furosemide | 151 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 146 | 29 |
| Gemfibrozil | Gemfibrozil | 131 | 11 |
| Ivermectin | Ivermectin | 130 | 96 |
| Linzess | Linaclotide | 130 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 123 | suppressed |
| Famotidine | Famotidine | 107 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 107 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 13 |
| Rinvoq | Upadacitinib | 105 | 13 |
| Trulicity | Dulaglutide | 95 | suppressed |
| Myrbetriq | Mirabegron | 93 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | suppressed |
| Lisinopril | Lisinopril | 83 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 82 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 79 | suppressed |
| Permethrin | Permethrin | 76 | 67 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 53 |
| Breo Ellipta | Fluticasone/Vilanterol | 72 | suppressed |
| Naproxen | Naproxen | 70 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | suppressed |
| Ketoconazole | Ketoconazole | 65 | 29 |
| Potassium Chloride | Potassium Chloride | 64 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 64 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 13 |
| Azithromycin | Azithromycin | 58 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 30 |
| Latanoprost | Latanoprost | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 35 |
| Eliquis | Apixaban | 48 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 19 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Ozempic | Semaglutide | 46 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 43 | suppressed |
| Ramipril | Ramipril | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 28 |
| Colesevelam Hcl | Colesevelam Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Nyamyc | Nystatin | 37 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Niacin Er | Niacin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Pulmicort Flexhaler | Budesonide | 25 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 24 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 14 |
| Azathioprine | Azathioprine | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin | Nystatin | 16 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Restasis Multidose | Cyclosporine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.99 · 8 records | AstraZeneca Pharmaceuticals LP | TEZSPIRE, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tezspire play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error